Gain Therapeutics Proposes Public Offering of Common Stock

BETHESDA, Md., June 13, 2024 ( GLOBE NEWSWIRE ) -- Gain Therapeutics, Inc. ("Gain" or the "Company") GANX has announced plans for a proposed public offering. The company intends to offer and sell shares of its common stock or, if necessary, pre-funded warrants as a substitute, depending on market conditions. This offering will be conducted as an underwritten transaction. The specifics of the offering, including the number of shares and price range, have yet to be determined.

About Gain Therapeutics, Inc.

Headquartered in Bethesda, Maryland, Gain Therapeutics, Inc. GANX is an innovative biotechnology firm engaged in the research and development of novel treatments for diseases linked with protein misfolding. Misfolded proteins are associated with a range of medical conditions, and Gain Therapeutics is at the forefront of targeting these dysfunctions to discover viable therapeutic solutions.

Market Response and Implications

The announcement of the proposed public offering is anticipated to create a significant response from the market as investors look to evaluate the impact of this event on Gain's financial strength and potential for future growth. Investors are advised to keep a close watch on market conditions and the forthcoming details of the proposed offering by Gain Therapeutics, Inc. GANX.

Biotechnology, Offering, Stocks